Ken Griffin’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.91M Buy
106,800
+6,200
+6% +$225K ﹤0.01% 5322
2026
Q2
$3.56M Sell
100,600
-6,500
-6% -$192K ﹤0.01% 5346
2026
Q1
$2.97M Sell
107,100
-210,800
-66% -$5.42M ﹤0.01% 5287
2025
Q4
$6.9M Buy
317,900
+59,100
+23% +$1.17M ﹤0.01% 3786
2025
Q3
$3.92M Buy
258,800
+67,600
+35% +$837K ﹤0.01% 4797
2025
Q2
$2.15M Sell
191,200
-82,200
-30% -$891K ﹤0.01% 5569
2025
Q1
$2.76M Buy
273,400
+24,300
+10% +$263K ﹤0.01% 4919
2024
Q4
$2.95M Sell
249,100
-47,900
-16% -$566K ﹤0.01% 4871
2024
Q3
$3.43M Buy
297,000
+69,000
+30% +$786K ﹤0.01% 4559
2024
Q2
$2.41M Sell
228,000
-30,700
-12% -$336K ﹤0.01% 4971
2024
Q1
$2.73M Buy
258,700
+40,400
+19% +$436K ﹤0.01% 4950
2023
Q4
$2.45M Buy
218,300
+93,100
+74% +$907K ﹤0.01% 5005
2023
Q3
$1.46M Buy
125,200
+102,500
+452% +$1.16M ﹤0.01% 5820
2023
Q2
$229K Sell
22,700
-6,300
-22% -$56.4K ﹤0.01% 9583
2023
Q1
$214K Buy
29,000
+10,700
+58% +$88.1K ﹤0.01% 10070
2022
Q4
$146K Sell
18,300
-1,200
-6% -$6.68K ﹤0.01% 10649
2022
Q3
$63K Sell
19,500
-3,200
-14% -$12.4K ﹤0.01% 11465
2022
Q2
$92K Buy
+22,700
New +$90.1K ﹤0.01% 11493

Other funds holding ROIV

Ken Griffin's ROIV Position: Q3 2026 in Review

Ken Griffin reduced its Roivant Sciences (ROIV) stake by 83% in Q3 2026, selling an estimated $167M and leaving 962,603 shares worth $35.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1915.

Ken Griffin first reported a position in ROIV in Q2 2022 and has held it in 18 quarters since. The position peaked at $197M in Q2 2026. 522 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

  • Ken Griffin held 962,603 shares of Roivant Sciences worth $35.2M as of Q3 2026.
  • Ken Griffin sold 4,613,658 Roivant Sciences shares in Q3 2026, an estimated $167M.
  • Roivant Sciences made up ﹤0.01% of Ken Griffin's portfolio in Q3 2026, its #1915 holding.
  • Ken Griffin first reported a position in Roivant Sciences in Q2 2022 and has held it in 18 quarters since.
  • Ken Griffin's Roivant Sciences position peaked at $197M in Q2 2026.
  • 522 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.